Quick Notes: July 9, 2020

  • Nova Eye Medical Limited acquired the ophthalmic assets of Molteno Ophthalmic Limited, including the proprietary Molteno3 glaucoma drainage device (GDD) platform. The Molteno3 GDD platform has been clinically validated to deliver consistent, long-term reduction in IOP in cases of severe or complex glaucoma. It has also been shown to offer the benefit of improved practice efficiency via a shorter surgical time.
  • Ophthalmic World Leaders (OWL) is hosting a series of webinars this summer called “Instigating Change: An Honest Discussion on Race in Ophthalmology.” Recordings of the first two hour-long webinars can be viewed at and To register for the final webinar, which will be held July 15 at 7 p.m. EST, visit

  • The “Zeiss Ophthalmic Virtual Experience: Summer Retina Meeting 2020” will take place on July 24. The virtual summer retina meeting will offer two educational tracks: Clinical Education and Practice Management During COVID-19 Era. The meeting will feature tips and updates from industry experts and a Q&A session with speakers. To register, visit

  • LayerBio was awarded $3 million from the Department of Defense, through the Congressionally Directed Medical Research Programs, to fund the development of the OcuRing. OcuRing is a novel drug delivery platform for cataract surgery with potential to eliminate the need for postoperative topical eye drops. The platform can be attached to most standard one-piece or three-piece IOLs and inserted into the eye using the standard injector systems.
  • Ocutrx Vision Technologies is developing a 5G-enabled augmented reality/cross reality (AR/XR) medical platform for release in 2021; the company plans for it to be the first such product for medical applications. Two headsets will be created: the Oculenz is intended for use by the ophthalmic patient for diagnosing and monitoring conditions, while the ORLenz is designed for physicians and surgeons and will allow for a surgery video feed with virtual information superimposed in the view of a surgeon.

  • As part of the FOCUS campaign to raise awareness of thyroid eye disease (TED), Horizon Therapeutics will donate $1 to Prevent Blindness every time a new video for the FOCUS campaign is shared online. The campaign is designed to help people recognize and manage the symptoms of TED, which frequently affects those suffering from Graves’ Disease, a condition of the autoimmune system. The FOCUS campaign will run through July 31, and the video can be found at

Quick Notes is published weekly. Unless otherwise noted, the information presented is based on press releases. Find earlier editions here. To submit a press release to be considered for publication, click here